Time in Therapeutic Range: Redefining "Optimal" Blood Pressure Control
- PMID: 33706871
- PMCID: PMC8091295
- DOI: 10.1016/j.jacc.2021.01.019
Time in Therapeutic Range: Redefining "Optimal" Blood Pressure Control
Keywords: cardiovascular; hypertension; outcomes variability.
Conflict of interest statement
Funding Support and Author Disclosures Dr. Bakris has received research funding, paid to the University of Chicago, from Bayer and Vascular Dynamics; has served as a consultant for Merck, Vascular Dynamics, Relypsa, Novo Nordisk, AstraZeneca, Ionis, Alnylam, and KBP; has served as bioscience editor for American Journal of Nephrology, Nephrology, and Hypertension; has served as section editor of UpToDate; and has served as associate editor for Diabetes Care, Hypertension Research, and Journal of Nephrology. Dr. Sternlicht has reported that he has no relationships relevant to the contents of this paper to disclose.
Comment on
-
Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension.J Am Coll Cardiol. 2021 Mar 16;77(10):1290-1299. doi: 10.1016/j.jacc.2021.01.014. J Am Coll Cardiol. 2021. PMID: 33706870 Free PMC article. Clinical Trial.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical